Travere Therapeutics (TVTX) Receivables - Net (2014 - 2026)

Travere Therapeutics has reported Receivables - Net for 13 years, with the latest figure at $87.3 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net rose 153.92% year-over-year to $87.3 million; the trailing twelve-month figure through Mar 2026 stood at $87.3 million (up 153.92% YoY), and the FY2025 full-year result was $80.1 million, up 195.4% from the prior year.
• Receivables - Net for Q1 2026 stood at $87.3 million, up from $80.1 million in the prior quarter.
• The five-year high for Receivables - Net was $87.3 million in Q1 2026, with the low at $12.7 million in Q3 2022.
• Historically, Receivables - Net has averaged $33.0 million across 5 years, with a median of $22.7 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net declined 5.45% — and 2025, when it jumped 229.3%.
• Travere Therapeutics' Receivables - Net stood at $16.6 million in 2022, then climbed by 27.23% to $21.2 million in 2023, then advanced by 28.03% to $27.1 million in 2024, then soared by 195.4% to $80.1 million in 2025, then rose by 8.99% to $87.3 million in 2026.
• The last three Receivables - Net figures came in at $87.3 million (Q1 2026), $80.1 million (Q4 2025), and $83.0 million (Q3 2025), per Business Quant data.